Crean, in the new role is expected to be responsible for all of Aqua’s acquisition, licensing and corporate initiatives.
Crean joins Aqua following a senior director for Business Development position with Allergan where he worked primarily in new business generation and transaction execution in support of growing many of Allergan’s business units including topical facial aesthetics, therapeutic skin care and movement-related neurological disorders.
Prior to his role in business development, David was the director of Project and Portfolio Management, where he was responsible for leading critical drug development programs.
Aqua CEO Jay Gooding said that David brings with him a level of experience and understanding that will be of great benefit to the senior management team.
"His business development background along with his knowledge of dermatology within the pharmaceutical market make him ideal for this position," Gooding said.